FRNM Freenome, Inc.
Services-Medical Laboratories · Nasdaq · SEC CIK 2017526 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY59.4%
TTM EPS YoY73.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-23.7%
ROA-17.7%
ROIC (approx.)29.0%
Asset turnover—
Leverage & solvency
Liabilities / assets34.4%
Debt / equity0.00x
Current ratio12.73x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.81x
Accruals ratio-3.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 |
|---|---|
| Income statement | |
| Revenue | — |
| SG&A expense | $2.98M |
| Operating income | -$2.98M |
| Net income | $837,468 |
| EPS (diluted) | — |
| Balance sheet | |
| Cash & equivalents | $78.56M |
| Receivables | $1.31M |
| Inventory | $0 |
| Current assets | $226.49M |
| PP&E, net | $155.78M |
| Goodwill | $10.51M |
| Intangibles | $3.30M |
| Total assets | $507.05M |
| Current liabilities | $40.53M |
| Total liabilities | $406.61M |
| Shareholders' equity | $100.44M |
| Shares outstanding | 67.94M |
| Cash flow statement | |
| Operating cash flow | -$864,653 |
| Investing cash flow | $600,000 |
| Financing cash flow | $0 |
· This company does not report gross profit in XBRL.
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.